REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 75 filers reported holding REVANCE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $1,075,000 | -16.9% | 82,862 | +0.9% | 0.00% | 0.0% |
Q1 2019 | $1,294,000 | -12.1% | 82,137 | +12.3% | 0.00% | -25.0% |
Q4 2018 | $1,472,000 | -24.3% | 73,137 | -6.6% | 0.00% | -20.0% |
Q3 2018 | $1,945,000 | -10.8% | 78,287 | -1.4% | 0.01% | -16.7% |
Q2 2018 | $2,180,000 | -11.5% | 79,417 | -0.7% | 0.01% | -14.3% |
Q1 2018 | $2,463,000 | -12.3% | 79,959 | +1.8% | 0.01% | -12.5% |
Q4 2017 | $2,809,000 | +72.9% | 78,560 | +33.2% | 0.01% | +60.0% |
Q3 2017 | $1,625,000 | +7.0% | 58,966 | +2.5% | 0.01% | 0.0% |
Q2 2017 | $1,518,000 | +32.8% | 57,516 | +4.6% | 0.01% | +25.0% |
Q1 2017 | $1,143,000 | -3.4% | 54,971 | -3.8% | 0.00% | 0.0% |
Q4 2016 | $1,183,000 | +30.9% | 57,171 | +2.6% | 0.00% | +33.3% |
Q3 2016 | $904,000 | +96.9% | 55,741 | +65.1% | 0.00% | +50.0% |
Q2 2016 | $459,000 | +28.2% | 33,761 | +64.4% | 0.00% | +100.0% |
Q1 2016 | $358,000 | 0.0% | 20,531 | +95.9% | 0.00% | 0.0% |
Q4 2015 | $358,000 | – | 10,481 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 4,405,039 | $118,936,000 | 9.40% |
Essex Woodlands Management, Inc. | 457,085 | $12,341,000 | 5.10% |
Evolutionary Tree Capital Management, LLC | 191,868 | $5,180,000 | 4.98% |
Ghost Tree Capital, LLC | 390,000 | $10,530,000 | 2.96% |
Antara Capital LP | 4,069,400 | $109,874,000 | 2.90% |
RICE HALL JAMES & ASSOCIATES, LLC | 896,754 | $24,212,000 | 1.40% |
Jericho Capital Asset Management L.P. | 714,000 | $19,278,000 | 1.22% |
Antara Capital LP | 1,600,000 | $43,200,000 | 1.14% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 120,000 | $3,240,000 | 1.04% |
TANG CAPITAL MANAGEMENT LLC | 287,500 | $7,763,000 | 0.95% |